Muthiah Vaduganathan MD, MPHAttending Cardiologist, Division of Cardiovascular Medicine, Brigham and Women’s Hospital; Instructor of Medicine, Harvard Medical School, Boston, Massachusetts
Dr. Vaduganathan is a cardiologist at Brigham and Women’s Hospital and Harvard Medical School (Boston, MA). His research focuses on drug development and clinical trials of cardiometabolic therapies. He has authored or co-authored more than 300 peer-reviewed publications. Dr. Vaduganathan serves on the editorial boards of the European Journal of Heart Failure, JACC Heart Failure (Social Media / CME Editor), & JACC (FIT / Early Career Section Editor). He serves as a co-chair on an FDA Think Tank committee on improving future clinical trials in HF. He participates as an investigator and Clinical Endpoints Committee member for ongoing advanced-phase trials in HF / post-MI LV dysfunction.
Dr. Vaduganathan is supported by the KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst (NIH/NCATS Award UL 1TR002541), serves on advisory boards for Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, Cytokinetics, and Relypsa, and participates on clinical endpoint committees for studies sponsored by Novartis and the NIH.